ALHAMBRA, Calif., July 23, 2024 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a leading provider-centric, technologypowered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that it will release financial results for the second quarter ended June 30, 2024, after the close of the stock market on Wednesday, August 7, 2024. The Company will discuss t ...

Partnership Will First Launch Value-Based Care Solution Offering to Hawai'i Provider Community Astrana and Elation will partner to empower primary care providers in value-based care. In partnership, the organizations plan to scale risk-bearing entities, including accountable care organizations and clinically integrated networks, anchored by existing and future affiliate providers. Together, the organizations will support independent physicians with the tools to deliver coordinated, high-quality care and to ...

ALHAMBRA, Calif., July 15, 2024 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, Anthem Blue Cross, one of California's largest health insurers, and Allied Pacific IPA, part of Astrana Health, a leading independent physician association serving the California community since 199 ...

Loading... Loading... Astrana serves over 10,000 providers and 1.0 million patients in value-based care arrangements. Thanks to its comprehensive delegation model, the Truist analyst was more confident in the company's ability to manage utilization and monitor trends. Truist upgraded the rating from Hold to Buy, with a price target of $50, up from $44. The analyst noted the multiple is supported by the company's attractive growth profile, relatively better visibility, strong profitability, and attractive ba ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___. Commission File No. 001-37392 Astrana Health, Inc. (Exact name of registrant as specified in its charter) Delaware 95-4472349 (State or Other Jurisdiction (I ...

Exhibit 99.1 Astrana Health, Inc. Reports First Quarter 2024 Results Company to Host Conference Call on Tuesday, May 7, 2024, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., May 7, 2024 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated fina ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ___ to ___ . Commission file number: 001-37392 Astrana Health, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpor ...

Exhibit 99.1 Astrana Health, Inc. Reports Fourth Quarter and Year-End 2023 Results Company to Host Conference Call on Tuesday, Feb. 27, 2024, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., February 27, 2024 /PRNewswire/ -- Astrana Health, Inc. (together with its subsidiaries and affiliated entities, "Astrana") (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced its consolidated financi ...

Revenue Performance - For the three months ended September 30, 2023, total revenue was $348.2 million, a 10% increase from $317.0 million in the same period of 2022, primarily driven by a $78.1 million increase in capitation revenue [238]. - For the nine months ended September 30, 2023, total revenue reached $1,033.6 million, reflecting a 22% increase from $850.0 million in the same period of 2022, with capitation revenue increasing by $229.2 million [240]. - Revenue for the three months ended September 30, 2023, was $326.5 million, an increase of $32.9 million, or 11%, compared to the same period in 2022 [268]. - Revenue for the nine months ended September 30, 2023, was $966.4 million, an increase of $184.2 million, or 24%, compared to the same period in 2022 [269]. - Revenue for the three months ended September 30, 2023, was $36.9 million, an increase of 22% compared to $30.3 million for the same period in 2022 [273]. - Revenue for the nine months ended September 30, 2023, was $102.5 million, reflecting a 15% increase from $89.3 million in the same period of 2022 [274]. Operating Performance - Operating expenses for the three months ended September 30, 2023, totaled $309.1 million, a 16% increase from $266.9 million in the same period of 2022 [233]. - Operating income for the three months ended September 30, 2023, was $40.3 million, a decrease of $6.0 million, or 13%, compared to the same period in 2022 [268]. - Operating income for the nine months ended September 30, 2023, was $90.5 million, an increase of $18.8 million, or 26%, compared to the same period in 2022 [269]. - Operating income for the three months ended September 30, 2023, was $6.4 million, up 27% from $5.1 million in the prior year [273]. - Operating income for the nine months ended September 30, 2023, decreased to $19.8 million, down 17% from $23.8 million in the previous year [274]. Net Income - Net income for the three months ended September 30, 2023, was $27.973 million, a 17% increase from $23.897 million in the same period of 2022 [233]. - Net income attributable to Apollo Medical Holdings, Inc. for the three months ended September 30, 2023, was $22.1 million, a decrease of $1.1 million compared to the same period in 2022 [264]. - The net income guidance for 2023 is set between $59.5 million and $71.5 million [276]. Cash Flow and Investments - Cash, cash equivalents, and investments totaled $277.0 million as of September 30, 2023, down from $293.6 million at the end of 2022 [283]. - Cash provided by operating activities for the nine months ended September 30, 2023, was $48.9 million, compared to cash used in operating activities of $2.8 million in the same period of 2022 [287]. - Cash used in investing activities for the nine months ended September 30, 2023, was $54.1 million, significantly higher than $20.3 million in the prior year, representing a 166% increase [286]. - Cash used in financing activities for the nine months ended September 30, 2023, was $8.6 million, a significant decrease from $26.0 million in the same period of 2022 [289]. Debt and Financing - The company entered into a Credit Agreement Amendment on November 3, 2023, increasing its credit facility to $700.0 million, including a new term loan of up to $300.0 million [223]. - The Amended Credit Agreement provides a total facility of $700.0 million, including a $400.0 million revolving credit facility and a new term loan of up to $300.0 million [296]. - As of September 30, 2023, the Company had $180.0 million in outstanding borrowings under the Amended Credit Agreement, with interest rates ranging from 1.25% to 2.50% based on leverage ratio [305]. - Future debt commitments include $181.2 million due in 2026, which represents the largest single-year obligation [295]. - A hypothetical 1% change in interest rates would have impacted the interest expense by $2.1 million for the three months ended September 30, 2023 [305]. Acquisitions and Partnerships - The company announced the acquisition of assets related to Community Family Care Medical Group, managing healthcare for over 200,000 members in Los Angeles [225]. - A partnership was established with Associated Hispanic Physicians, which includes over 150 primary care providers and 450 specialists, expected to onboard by March 2024 [226]. Other Financial Metrics - General and administrative expenses for the three months ended September 30, 2023, were $29.4 million, an increase of $8.0 million, or 38%, compared to the same period in 2022 [244]. - Interest expense for the three months ended September 30, 2023, was $3.8 million, an increase of $1.4 million, due to higher interest rates [252]. - Interest income for the three months ended September 30, 2023, was $3.3 million, compared to $0.2 million for the same period in 2022 [254]. - Unrealized loss for the three months ended September 30, 2023, was $0.3 million, a decrease of $6.4 million compared to the same period in 2022 [256]. - Other income for the three months ended September 30, 2023, was $1.9 million, an increase of $3.2 million compared to a loss of $1.3 million for the same period in 2022 [258]. Patient Management - The company managed approximately 0.9 million patients as of September 30, 2023, down from 1.2 million in the same period of 2022 [235]. Excluded Assets - Total Excluded Assets as of September 30, 2023, amounted to $124.8 million, slightly down from $127.9 million as of December 31, 2022 [292]. - Excluded Assets net loss for the nine months ended September 30, 2023, was $5.0 million, an improvement compared to a loss of $16.0 million in the same period of 2022 [292]. - Cash and cash equivalents in Excluded Assets decreased to $11.6 million as of September 30, 2023, from $30.2 million at the end of 2022 [292]. - Total operating expenses for Excluded Assets increased to $3.3 million for the nine months ended September 30, 2023, compared to $2.9 million in the prior year [292].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___. Commission File No. 001-37392 Apollo Medical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 95-4472349 (State or Other Jurisdiction (I.R.S. Employer Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES E ...